Sanofi (SNY) Cash from Financing Activities (2019 - 2026)

Sanofi has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$2.1 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 52.44% year-over-year to -$2.1 billion; the TTM figure through Jun 2026 stood at -$20.0 billion (down 68.1% YoY), while the FY2025 annual figure was -$9.5 billion, down 52.58% from the prior year.
• Cash from Financing Activities came in at -$2.1 billion for Q2 2026 at Sanofi, down from -$1.8 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $825.6 million in Q1 2024 to a low of -$9.6 billion in Q4 2025.
• Average Cash from Financing Activities over 5 years is -$4.2 billion, with a median of -$4.4 billion recorded in 2025.
• Year-over-year, Cash from Financing Activities tumbled 510.48% in 2025 and jumped 52.44% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$5.9 billion in 2022, then plunged by 45.88% to -$8.7 billion in 2023, then gained by 28.92% to -$6.2 billion in 2024, then plunged by 55.13% to -$9.6 billion in 2025, then surged by 78.04% to -$2.1 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.1 billion in Q2 2026, -$1.8 billion in Q1 2026, and -$9.6 billion in Q4 2025.